Anúncio
Anúncio
TVTX
Travere Therapeutics, Inc. Common Stock
39.49
USDPatrocinado
+1.28
+3.36%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
39.38
-0.11
-0.27%
Relatórios de Lucros TVTX
Rácio de surpresa positiva
TVTX separação 16 de 40 últimas estimativas.
40%
Próximo Relatório
Data do Próximo Relatório
18 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$145.08M
/-$0.12
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-12.00%
/-142.86%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+93.99%
/-83.56%
Travere Therapeutics, Inc. Common Stock earnings per share and revenue
On 30 de out. de 2025, TVTX reported earnings of 0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 232.08% surprise. Revenue reached 164.86 milhão, compared to an expected 108.66 milhão, with a 51.71% difference. The market reacted with a +18.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analistas forecast an EPS of -0.12 USD, with revenue projected to reach 145.08 milhão USD, implying an diminuir of -142.86% EPS, and diminuir of -12.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Travere Therapeutics, Inc. Common Stock reported EPS of $0.28, beating estimates by 232.08%, and revenue of $164.86M, 51.71% above expectations.
How did the market react to Travere Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 18.58%, changed from $29.65 before the earnings release to $35.16 the day after.
When is Travere Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 18 de fev. de 2026.
What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?
Based on 16
analistas, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $145.08M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio